Exjade will be the first ORAL iron-chelation therapy

January 2006

Exjade will be the first ORAL iron-chelation therapy.

It's investigational in Canada and just approved in the U.S.

Patients who need blood transfusions for sickle cell disease, thalassemia, and other blood disorders often develop iron overload.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

privacy issues related to dispensing Plan B (levonorgestrel)
People are asking about glucosamine and chondroitin for osteoarthritis
Women's Health using Paxil during pregnancy
Cholesterol whether Lipitor is better than Zocor for preventing heart attacks and strokes
Cholesterol Lots of supplements for cholesterol now contain policosanol
Exjade will be the first ORAL iron-chelation therapy
Pediatrics what dose of OTC cough and cold meds to give to children UNDER two years
Infectious Diseases new virulent strains of Clostridium difficile
Infectious Diseases new concern about blood glucose problems in patients taking Tequin (gatifloxacin)
Cardiology whether Biaxin increases mortality in patients with heart disease
Cardiology Viagra for severe Raynaud's
Supplements what's actually in some popular weight loss products
Supplements supplements that claim to be helpful in preventing and treating the avian flu
Migraine A new study suggests that a combination of OTC pain relievers is better than Imitrex (sumatriptan) for treating acute migraines